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ABSTRACT 
Sixty six patients of either sex with a diagnosis of schizophrenia as per DSM lll-R criteria 
were enrolled in an open, non-comparative study. They were treated with loxapine over a duration 
of 6 weeks. The assessment of the patients was carried out using the Positive and Negative 
Syndrome Scale (PANSS) and Clinical global Impression (CGI) Scale. The side effects were noted 
on the Extrapyramidal Rating Scale and Asberg Scale for side effects. There was a statistically 
significant improvement in all the item scores of PANSS except 'Guilt Feeling' and 'Depression'. A 
similar significant improvement was also observed in the factor scores and cluster scores of PANSS. 
On analysis there was substantial improvement in the negative scale ratings on PANSS in the 
negative subtyped group (13 sub). The average dose ofloxapine received by patients at the time 
of completion of the study was 96.75+36 mg per day. The most commonly reported side effects 
were dryness of mouth, constipation & drowsiness. Loxapine appeared to be effective and well 
tolerated in the treatment of acute exacerbation in schizophrenia. Evaluation of loxapine in the 
treatment of negative symptoms of schizophrenia merits particular attention. 
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Loxapine is a neuroleptic of the 
dibenzoxazepine class. The pharmacological 
profile includes blockade of 5-HT, dopaminer-
gic and histamine receptors, but the muscarinic 
and receptor blockades are weak, (Vanelle et 
al., 1994). 
Loxapine closely resembles the other tra-
ditional antipsychotics in its therapeutic efficacy 
and side effects profile. It has been mainly used 
as an 'antiproductive' drug with better response 
in patients with paranoid schizophrenia. It has 
been effective in treating acute as we.ll as 
chronic cases of schizophrenia (Heel et al., 
1978; Ayd, 1977). 
In the studies on loxapine published ear-
lier including those conducted in India (Seth et 
al., 1979; Malik et al., 1980; Bagadia et al., 
1980; Dube and Kumar, 1976), the standard 
scales such as Brief Psychiatric Rating Scale 
(BPRS), Clinical Global Impression Scale (CGI) 
& Nurses, Observation Scale for Inpatient 
Evaluation (NOSIE) have been used for evalu-
ation of the patients. However, it has been sug-
gested that Loxapine actions justify further stud-
ies using better targeted scales such as PANSS 
(Positive and Negative Syndrome Scale) 
considering the deficit reduction suspected in 
the initial stages (Vanelle et al., 1994). 
MATERIAL & METHOD 
PANSS was initially formulated in the 
early eighties as a special adaptation of two 
psychiatric rating instruments -BPRS & 
psychopathology rating schedule. Later it was 
modified, expanded and standardised with 
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greater psychometric sophistication for positive/ 
negative evaluation. It consists of positive scale 
(7 items measuring symptoms that are 
superadded to a normal mental status), nega-
tive scale (7 items assessing features absent 
from a normal mental status), composite scale 
(based on the differential between positive and 
negative scales to specify the degree of pre-
ponderance of one syndrome over the other) & 
a general psychopathology scale (16 items 
assessing overall severity of the schizophrenic 
disorder) (Kay et al., 1986). This is a 
comprehensive scale that measures not only 
general and somatic symptoms but also 
focuses on the positive and negative aspects 
of the disease. 
The CGI was used to asses overall 
improvement in the clinical condition. For 
measuring the side effects of the drug & the 
extent of extrapyramidal symptoms, the Asberg 
scale & the Extrapyramidal Symptoms Rating 
Scale were used. 
66 patients of either sex between 18 and 
60 years of age diagnosed to have exacerba-
tion of schizophrenia as per DSM III R criteria 
were enrolled in a 6 week open, non 
comparative study conducted at Nur Manzil 
Psychiatric Centre, Lucknow. These included 
both new cases as well as acute exacerbation 
of chronic schizophrenia. Patients with follow-
ing characteristics were excluded from the 
study: known hypersensitivity to 
dibenzoxazepine derivatives; severe hepatic, 
renal, cardiovascular, endocrine or other 
neurologic diseases including mental retarda-
tion; treatment with psychotropic or other an-
tipsychotic drugs 24 hours prior to the start of 
the study; patients below 18 years and above 
60 years of age and pregnant and lactating 
women. 
Following enrolment, the patients were 
rated on the PANSS & the CGI scales by an 
independent observer unaware of the treatment 
to be given. The patients were then 
hospitalized. 
The treatment was started with loxapine 
at a dose of 25 mg twice a day and rapidly 
increased with increments every week to the 
effects and tolerated dose. The upper limit of 
250 mg for the daily dose was not exceeded in 
any patient. Concomitant use of psychotropic 
drugs was not allowed. Antiparkinsonian drugs 
TABLE 1 
CHANGE IN THE MEAN SYNDROME SCORES AND CLUSTER SCORES OVER THE DURATION OF STUDY 
Syndrome/cluster scores 
Positive synd. score 
Negative synd. score 
General psychopathology 
score 
Anergia 
Thought disturbance 
Activation 
Paranoid belligerence 
Depression 
Basal 
26.31 
18.80 
40.85 
9.61 
14.17 
7.61 
11.41 
6.48 
Weekl 
23.83** 
17.31" 
37.31" 
8.92** 
13.38" 
6.73** 
9.90" 
6.13 
Week 2 
19.19" 
15.51" 
31.79** 
8.11" 
11.21" 
5.96** 
7.57** 
5.91* 
Week 4 
14.17" 
13.81" 
26.13" 
6.83*" 
8.72" 
4.67** 
5.59** 
5.69* 
Week 6 
11.24" 
11.41" 
22.78" 
6.22" 
6 81" 
3.85" 
4.43" 
5.50** 
* p < 0.05 " < 0.01 
Friedmann two way ANOVA followed by multiple comparison tests 
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TABLE 2 
MEAN PERCENTAGE MAXIMUM POSSIBLE CHANGE FROM BASELINE FOR 
SYNDROME SCORES & CLUSTER SCORES 
Sr. No. 
1 
2 
3 
4 
5 
6 
7 
8 
Syndrome/Cluster 
Positive Syndrome 
Negative Syndrome 
general Psychopathology 
Anergia 
Thought disturbance 
Activation 
Paranoid Belligerence 
Depression 
Week 1 
14 
19 
16 
17 
9 
20 
17 
9 
Change from baseline {%) 
Week 2 
38 
25 
38 
28 
33 
40 
45 
27 
Week 4 
66 
36 
61 
46 
58 
67 
70 
30 
Week 6 
80 
51 
73 
60 
75 
83 
83 
45 
were permitted in the event of extrapyramidal 
side effects. Other drugs indicated for the treat-
ment of concurrent physical diseases arising 
during the trial period were allowed. A record 
of all such medications was maintained. The 
patients were assessed at the end of 1,2,4 & 6 
weeks using the rating scales mentioned above. 
The study completed at the end of 6 
weeks unless terminated earlier due to serious 
adverse or toxic effect related to treatment. 
The individual item scores and factor 
scores assessed by using the rating scales at 
baseline and the subsequent evaluation were 
analysed by ANOVA, Friedmann two way 
followed by multiple comparisons. 
RESULTS 
Out of the sixty six patients enrolled, fifty 
four patients completed the study successfully 
and were considered for analysis. 
There were 6 cases of protocol isolations, 
like use of additional antipsychotics (5 cases) 
or ECT (1 case). There were 5 dropouts (4 for 
logistical reasons and 1 due to unsatisfactory 
response). One case had to be withdrawn due 
to extrapyramidal side effects. This case has 
been included in the analysis of side 
effects. 
The demographic profile of the 54 
analyzable patients is as follows : the number 
of female patients completing the study was 
23 (42.6%) and that of male patients was 
31(57.4%). The mean age of patients was 29.5 
years (s.d. 10.7 years). There were 23 patients 
(42.6%) with diagnosis of paranoid 
schizophrenia, 13(24.1%) with disorganised 
schizophrenia, 10 (18.5%) with undifferentiated 
schizophrenia and 8 (14.8%) with catatonic 
schizophrenia . 15 patients were new cases, 27 
patients had one or two previous attacks of the 
disease, while 12 patients had 3 to 6 attacks in 
the past. 
The change in the individual item rating 
scores of the positive scale, the negative scale 
and the general psychopathology scale in 
PANSS showed that for all the item except guilt 
feelings, tension, anxiety and depression, there 
was a statistically significant improvement. It 
was apparent in many item from week one 
itself (17 out of 28 items) and in most by the 
end of 2 weeks (25 out of 28 items). 
Amongst the positive symptoms-
delusions, hallucinations, suspiciousness, 
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TABLE 3 
MEAN PERCENTAGE MAXIMUM POSSIBLE CHANGE FROM BASELINE FOR NEGATIVE SCALE 
ITEMS IN PATIENTS WITH NEGATIVE SUBTYPE OR MIXED TYPE OF DISEASES 
Sr. No. 
1 
2 
3 
4 
5 
6 
7 
Item 
Blunted affect 
Emotional withdrawal 
Poor Rapport 
Passive/apathetic social 
withdrawal 
Difficulty in abstract thinking 
Lack of spontaneity & flow of 
conversation 
Stereotyped thinking 
No. of 
patients 
12 
15 
16 
14 
18 
15 
7 
Change from baseline (%) 
Week 1 
7 
15 
18 
16 
10 
21 
31 
Week 2 
19 
26 
42 
36 
28 
44 
44 
Week 4 
36 
40 
61 
46 
43 
69 
91 
Week 6 
48 
48 
69 
55 
64 
85 
91 
hostility & unco-operativeness improved by the 
end of the first week, while conceptual disor-
ganisation, unusual thought content improved 
by the second week. All negative items im-
proved by the first week except social 
withdrawal, motor retardation and social 
avoidance that improved by second week. 
It was however, noticed that the mean 
initial score for each item was less than 4 in 
most cases (4 in PANSS indicates a moderate 
severity).,The inference was that pooling of 
various cases had masked the score. Hence 
syndromes and clusters were analysed. 
Analysis of the syndrome scores i.e. 
positive syndrome, negative syndrome, and 
general psychopathology also showed a highly 
significant improvement from week one and was 
continued till the end of the study period. A 
similar picture emerged from the analysis of 
cluster scores namely anergia, thought 
disturbance, activation, paranoid belligerence 
and depression. Table 1 summarizes the change 
in syndrome scores and cluster scores. 
To get a better idea of the real change, 
the mean percentage maximum possible im-
provement was calculated (table II). It was then 
noted that improvement for all syndromes and 
cluster at 6 weeks was more than 60% except 
for negative syndrome (51%) and depression 
(45%). On a closer look at the data it was noted 
that although few patients had a high score for 
some negative items, the mean initial score for 
pooled patients was two, suggesting mild dis-
ease. Hence, we tried to study cases with a 
predominance of negative symptoms 
separately. 
The PANSS scale gives two methods of 
identifying negative subtypes of 
schizophrenia. A quantitative measure indicated 
by negative composite scores. This measure 
identified 13 cases. Another is a count of 
positive and negative items. At least three 
moderate ratings on the negative scale and less 
than three on positive scale indicates negative 
schizophrenia, while three or more than three 
moderate scores on both scales indicate : mixed 
type (8). This measure identified 6 cases of 
mixed schizophrenia with a predominance of 
negative symptoms. 
The diagnoses in these 19 patients were 
as follows: disorganised schizophrenia (9) 
undifferentiated schizophrenia (6), paranoid 
schizophrenia (3) and catatonic schizophrenia 
(1). Analysis of the percentage maximum 
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possible change from baseline (table III) for the 
items of negative scale in these patients 
revealed a marked improvement by the end of 
the study. 
There was a significant improvement in 
the severity of illness on Clinical Global 
Impression Scale (p<0.001) . 
Side effects were recorded both on 
Asberg's Side Effects Scale and the extrapy-
ramidal rating scale. General side effects as per 
Asberg's Scale are listed in Table IV. Dry mouth, 
drowsiness, constipation, fatigue were most 
common, but of mild to moderate severity. 
The common extrapyramidal effects 
noted were : tremor, rigidity, akathesia and dimi-
nution of facial expression (table V). There were 
70 events in 31 patients. Of these 24 cases had 
to be administered benzhexol in a dose of 2 to 
6 mg/day. The case that was withdrawn due to 
side effects has been included in this analysis 
The average daily dose of loxapine used 
during the study period was 54.15+12.5 mg 
(baseline), 81.6+16.21 mg (wk1) 97.68+25.58 
mg (wk2), 105 133.8 mg (wk4) and 96.75+36 
TABLE 4 
SIDE EFFECTS GENERAL (ASBERG SCALE) (N=56) 
Side effects 
Physical tiredness 
Sleeping disturbance 
Headache 
Dizziness 
Orthostatic hypotension 
Palpitations 
Tremor 
Perspiration 
Dryness of mouth 
Constipation 
Micturition disturbance 
Drowsiness 
Sexual dysfunction 
Total Events in 33 cases 
No. of patients 
4 
3 
1 
1 
5 
3 
10 
1 
17 
4 
1 
8 
1 
59 
TABLE 5 
SIDE EFFECTS : EXTFJA PRAMIDAL 
SYMPTOMS (N=56) 
Extrapyramidal symptoms 
Facial expression 
Dysarthria 
Rigidity (neck) 
Rigidity (arm) 
Tremor (face and head) 
Tremor (arms) 
Tremor (legs) 
Gait 
Posture 
Akathesia 
Total events 
No. of patients with EPS 
No. of Patients 
5 
4 
5 
8 
5 
19 
3 
5 
6 
9 
70 
31 
mg (wk6). 
The concomitant medications used 
during the study were as follows: benzhexol 
hydrochloride (dose range 2 to 6 mg/day, 24 
patients), nitrazepam (5 to 10 mg/day, 4 
patients), lorazepam (1 to 2 mg/day, 2 patients) 
& imipramine (75 mg/day; 1 patient). 
DISCUSSION 
Schizophrenia has been recognised as a 
complex disease marked by various symptoms 
affecting aspects of human cognition, emotion 
and behaviour. Bleuler, who coined the term 
'Schizophrenia' proposed a conceptual division 
of symptoms into 'accessory' (unstable florid 
symptoms) and 'fundamental' (more permanent 
breakdowns in mental function). Other terms 
that have been used include 'productive/deficit 
or positive/negative' symptoms (Mortimer & 
Mckenna, 1992). 
Although recognised as early as the be-
ginning of this century, the research interest in 
negative symptoms was overshadowed by the 
weightage given to the positive symptoms. 
The interest in negative symptoms was 
renewed in the late seventies and early eight-
ies resulting in the realization that the negative 
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symptoms were ubiquitious in nature, excess 
morbidity was associated with them, and they 
were generally not responsive to pharmaco-
logical therapy. 
The last of these observations has 
spurred a lot of research activity into the effi-
cacy of antipsychotics in treating the negative 
symptoms (Miller et al., 1994). Development 
of newer psychiatric rating instruments such as 
PANSS, has also helped to standardise the 
positive-negative evaluation. 
Earlier studies on loxapine did not use 
scales that addressed positive and negative 
symptoms, hence PANSS was used in this 
study. 
In our study marked improvement was 
seen in most items, syndrome and cluster 
scores by first week. This speed of response is 
in keeping with various other studies, (Serban, 
1997), some of which demonstrated an effect 
even within 48 hours (Moriarty et al., 1979; 
Zisook & Click, 1980). 
Dose used was gradually increased from 
50 mg to 150 mg. The mean dose used at the 
end of the study was 96.75 mg, indicating a 
slight reduction in dose after the fourth week. 
Such a reduction has been recommended, and 
the maintenance dose in expected to be be-
tween 60 and 100 mg (Ayd, 1977). Malik & 
Kumar (1980) in their study also required a 
mean dose of 91.5 mg. 
Loxapine is known for its action on para-
noid schizophrenia (Vanelle et al., 1994; Heel 
et al., 1978; Ayd, 1977). In the present study it 
showed excellent response in positive symp-
toms. 
On closer scrutiny there were only 19 
cases with a predominance of negative 
symptoms, a number too small for meaningful 
statistical analysis. When these cases were 
analysed item wise on a percentage maximum 
possible improvement basis an impressive im-
provement was seen in all negative items. 
Most of the side effects were of mild to 
moderate severity, with only one dropout due 
to adverse reactions. Ayd (1977) mentions that 
clinically it is difficult to predict who will respond 
to loxapine and who will not, a fact borne out 
by the two cases who were withdrawn from the 
study due to an unsatisfactory response. 
These observations indicate that 
loxapine certainly deserves further evaluation 
in the treatment of negative symptoms of 
schizophrenia. Trivedi & Aga (1994) have ear-
lier recommended that diphenyibutyl 
priperidines such as pimozide or penfluridol with 
their calcium channel antagonism should be 
tried in negative symptoms; and Venelle et al. 
(1994) recommends clozapine or risperidone. 
The possibility that loxapine which is an 
established, effective and safe neuroleptic may 
emerge as a viable alternative fc; management 
of negative symptoms needs to be further 
investigated. 
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